1. Patient characteristics of long-term responders to mogamulizumab: results from the MAVORIC study. (October 2021) Authors: Kim, Youn H.; Khodadoust, Michael; de Masson, Adele; Moins-Teisserenc, Hélène; Ito, Takahiro; Dwyer, Karen; Herr, Fiona; Bagot, Martine Journal: European journal of cancer Issue: Volume 156(2021)Supplement 1 Page Start: S48 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Characterization and outcomes in patients with mogamulizumab-associated skin reactions in the MAVORIC trial. (October 2021) Authors: Musiek, Amy C.M.; Whittaker, Sean; Horowitz, Steven M.; Bagot, Martine; Huen, Auris; Fisher, David C.; Haun, Paul; Vermeer, Maarten H.; Ito, Takahiro; Dwyer, Karen; Herr, Fiona; Kim, Youn H. Journal: European journal of cancer Issue: Volume 156(2021)Supplement 1 Page Start: S46 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Long‐term disease control and safety with the anti‐CCR4 antibody mogamulizumab: Post‐hoc analyses from the MAVORIC trial of patients with previously treated cutaneous T‐cell lymphoma. Issue 8 (28th June 2022) Authors: Bagot, Martine; Dalle, Stéphane; Sokol, Lubomir; Tsianakas, Athansios; Musiek, Amy; Ortiz‐Romero, Pablo L.; Poligone, Brian; Duvic, Madeleine; Elmets, Craig; Leoni, Mollie; Dwyer, Karen; Ito, Takahiro; Herr, Fiona; Kim, Youn H. Journal: Dermatologic therapy Issue: Volume 35:Issue 8(2022) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗